Newtyn Management’s Adverum Biotechnologies ADVM Stock Holding History

Newtyn Management’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-46,189	Closed	-$653K	–	42
2024 Q1	$653K	Sell	46,189 -36,121	-44%	-$549K	0.13%	38
2023 Q4	$620K	Sell	82,310 -20,190	-20%	-$184K	0.12%	42
2023 Q3	$1.54M	Buy	102,500 +2,500	+3%	+$44.9K	0.38%	34
2023 Q2	$1.59M	Sell	100,000 -52,840	-35%	-$556K	0.38%	33
2023 Q1	$1.1M	Sell	152,840 -10,660	-7%	-$75.4K	0.22%	55
2022 Q4	$947K	Buy	163,500 +73,500	+82%	+$557K	0.2%	53
2022 Q3	$855K	Sell	90,000 -13,500	-13%	-$177K	0.19%	60
2022 Q2	$1.24M	Buy	+103,500	New	+$1.08M	0.24%	57

Other funds holding ADVM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Newtyn Management's ADVM Position: Q2 2024 in Review

Newtyn Management sold out of Adverum Biotechnologies (ADVM) in Q2 2024, closing a stake of 46,189 shares — an estimated $653K sold.

Newtyn Management first reported a position in ADVM in Q2 2022 and held it in 8 quarters. The position peaked at $1.59M in Q2 2023. 68 funds tracked by Wall St. Rank hold ADVM as of Q2 2024.

Newtyn Management reported no remaining Adverum Biotechnologies position as of Q2 2024 after selling out during the quarter.
Newtyn Management sold 46,189 Adverum Biotechnologies shares in Q2 2024, an estimated $653K.
Newtyn Management first reported a position in Adverum Biotechnologies in Q2 2022 and held it in 8 quarters.
Newtyn Management's Adverum Biotechnologies position peaked at $1.59M in Q2 2023.
68 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2024.

Based on Newtyn Management's 13F filing for Q2 2024, filed 14 Aug 2024.